UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in NewAmsterdam Pharma (NASDAQ:NAMS ...
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) reached a new 52-week high during trading on Wednesday after Scotiabank raised their price target on the stock from $35.00 to $47.00. Scotiabank ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback